Information Provided By: 
Fly News Breaks for August 8, 2017
DEPO
Aug 8, 2017 | 08:26 EDT
As previously reported, Janney Capital analyst Ken Trbovich downgraded Depomed to Neutral from Buy, saying he reads the company's surprising lowering of its full-year guidance for revenues and raising of its expense guidance as an admission that the challenges facing its business are far greater to overcome than just fixing its sales force alignment. Trbovich, who noted that this was the fifth time in the past six quarters that Depomed has lowered the upper end of its revenue view, cut his fair value estimate on the stock to $8 from $18.
News For DEPO From the Last 2 Days
There are no results for your query DEPO
